Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
210.50
-0.50 (-0.24%)
Feb 27 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range 207.50 - 211.00
52 week 91.00 - 220.00
Open 210.50
Vol / Avg. 146,067.00/254,304.00
Mkt cap 5.82B
P/E     -
Div/yield     -
EPS -3.78
Shares 27.67M
Beta     -
Inst. own     -
May 5, 2015
Q1 2015 Bavarian Nordic A/S Earnings Release Add to calendar
Apr 23, 2015
Bavarian Nordic A/S Annual Shareholders Meeting Add to calendar
Mar 11, 2015
Q4 2014 Bavarian Nordic A/S Earnings Release Add to calendar
Mar 2, 2015
Bavarian Nordic A/S at Cowen Health Care Conference - 10:50PM GMT+1 - Add to calendar
Jan 12, 2015
Bavarian Nordic A/S at JPMorgan Healthcare Conference (1-on-1 Meetings)
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -8.13% -3.85%
Operating margin -22.91% 2.76%
EBITD margin - 6.37%
Return on average assets -5.83% -3.12%
Return on average equity -8.13% -4.73%
Employees 415 -
CDP Score - -

Address

Hejreskovvej 10A, Munkegarde
KVISTGAARD, 3490
Denmark

Website links

Description

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company�s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Officers and directors

Gerard W. M. van Odijk M.D. Chairman of the Board
Age: 57
Paul Chaplin Ph.D. President, Chief Executive Officer
Age: 47
Anders Gersel Pedersen M.D. Deputy Chairman of the Board
Age: 63
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 48
James B. Breitmeyer Executive Vice President, Division President of Cancer Vaccine
Peter Kurstein Director
Age: 57
Claus Braestrup Independent Director
Age: 69
Erik Gregers Hansen Independent Director
Age: 61